GH Research

Recent Finacing

Series B

Recent Raise

$125M

GH Research is a clinical-stage biopharmaceutical company developing 5-MeO-DMT therapies for psychiatric and neurological disorders, advancing an inhaled GH001 in Phase 1/2 for treatment-resistant depression and planning injectable GH002.

Founded 2018

Dublin, Ireland

11-50

Publicly Traded

ghres.com

Highlights

Focus Areas

Biopharma

Biotechnology

Pharmaceutical

Recent Investors

A

Financials

$125M

Total Raised

1

Funding round

11

Investors

Team

Upgrade to view the team

See the team members at GH Research.